Supervisory Board

Jan Hendrik Egberts

Jan has over 25 years of executive experience in the pharmaceutical and medical device sectors, most recently as CEO at Agendia Inc., a molecular diagnostics company. Prior to this, he was CEO of OctoPlus N.V., a specialty pharmaceutical company, which was acquired by Dr. Reddy’s Laboratories Ltd. in 2013. Jan also served as a senior healthcare advisor for 3i Group plc, a private equity firm and as President, Chairman and CEO of NovaDel Pharmaceuticals Inc., where he developed a portfolio of pre-clinical and clinical compounds, gaining FDA approval for two compounds. In addition, Jan has held multiple business development and general management positions at Johnson & Johnson, Merck & Co. and Mölnlycke Health Care. He graduated from Erasmus University Medical School in the Netherlands and he obtained his MBA from Stanford after which he worked as a management consultant for McKinsey & Co. Jan continues to serve on the supervisory board of CHDR (Center for Human Drug Research), Pharming Group N.V., LeadPharma and Implanet S.A.

Rob de Ree, MSc

Rob is trained as a pharmacist and has over 20 years experience in the pharmaceutical and medtech industry in sales, marketing, business development and general management. During his 8-year tenure at Medtronic, he was responsible for building the European venture business for the Octopus and other minimally invasive cardiac surgery products. In 2004, he was appointed European marketing director for the Cardiac Rhythm Management division, after which he relocated to the Medtronic European headquarters in Switzerland. Rob joined BMEYE (hemodynamic monitoring) in June 2007 as the VP Sales & Marketing and was appointed CEO in January 2008. In 2012, under his leadership, BMEYE was successfully acquired by Edwards Lifesciences, the worldwide market leader in hemodynamic monitoring. Rob was CEO of Dezima Pharma which was sold to Amgen in 2015. He is currently Operating Partner at Biogeneration Ventures and Chairman of the Supervisory Board of Ventinova Medical.

Oskar Slotboom – BioGeneration Ventures

Oskar has a broad biotech and business background and is currently partner at BioGeneration Ventures. Oskar started his career in McKinsey & Company as a management consultant. After that he held positions in Crucell, first in business development and later he became responsible for the Pediatric Franchise. After the acquisition of Crucell by Johnson & Johnson, Oskar led the Vaccines & Infectious Diseases business unit in Johnson & Johnson’s pharma joint venture Xian Janssen in Beijing, China. Prior to joining BioGeneration Oskar was Chief Commercial Officer of Avantium, a leading chemical technology company and a forerunner in renewable chemistry.

Oskar has a degree in chemical engineering from the Twente University and holds a MBA from INSEAD.

Oskar serves on several boards of companies in BioGeneration’s portfolio.